PURPOSE: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration. METHODS: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage >50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features. RESULTS: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 ± 0.22 (logarithm of the minimum angle of resolution ± standard deviation) and 342 ± 56 µm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 ± 0.41 (P = 0.04), and mean central macular thickness decreased to 236 ± 26 µm (P < 0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered. CONCLUSION: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.
PURPOSE: To evaluate the effects of intravitreal ranibizumab injections in the treatment of choroidal neovascularization with large submacular hemorrhage secondary to age-related macular degeneration. METHODS: Prospective interventional case series. Patients presenting occult choroidal neovascularization with flat large submacular hemorrhage >50% of the entire lesion were considered. The protocol required 3 monthly consecutive injections, followed by repeat injections over the 12-month follow-up on the basis of optical coherence tomography parameters and angiographic features. RESULTS: Twenty-three patients were enrolled in the study and prospectively followed up. Mean best-corrected visual acuity and mean central macular thickness at the baseline were 0.82 ± 0.22 (logarithm of the minimum angle of resolution ± standard deviation) and 342 ± 56 µm, respectively. At 12-month examination, mean visual acuity improved significantly to 0.68 ± 0.41 (P = 0.04), and mean central macular thickness decreased to 236 ± 26 µm (P < 0.0001). A progressive resolution of macular bleeding was registered in 22 of 23 patients. No side effect or complication was registered. CONCLUSION: Intravitreal ranibizumab can be considered a beneficial approach for the management of choroidal neovascularization with flat large submacular hemorrhage secondary to age-related macular degeneration.
Authors: Michael M Altaweel; Ebenezer Daniel; Daniel F Martin; Robert A Mittra; Juan E Grunwald; Michael M Lai; Alexander Melamud; Lawrence S Morse; Jiayan Huang; Frederick L Ferris; Stuart L Fine; Maureen G Maguire Journal: Ophthalmology Date: 2014-10-11 Impact factor: 12.079
Authors: Seung Ha Lee; Sang Joon Lee; Yong Il Shin; Hyung Bin Lim; Jung Yeul Kim; Yong Seop Han; Ki Yup Nam Journal: Eye (Lond) Date: 2021-01-09 Impact factor: 4.456
Authors: Kyung-Hoon Shin; Tae Gon Lee; Jae Hui Kim; Jong Woo Kim; Chul Gu Kim; Dong Won Lee; Jung Il Han; Young Ju Lew; Han Joo Cho Journal: Korean J Ophthalmol Date: 2016-09-29
Authors: Giamberto Casini; Pasquale Loiudice; Martina Menchini; Francesco Sartini; Stefano De Cillà; Michele Figus; Marco Nardi Journal: Int J Retina Vitreous Date: 2019-12-11